Login here to update your profile  
My Profile

Kelly Barrios-Marrugo,  M.S


Primary Department:

profile Image
Contacts
Email: kbarrios@health.usf.edu
Office: SRB, 22214
Mailing address 12902 Magnolia Drive SRB-22214 Celis Lab
Tampa, FL 33612
 
Education
  • MS, Medical Science, University of South Florida ,USA - 2012.
  • MS, Immunology, University of Cartagena , Cartagena, Colombia - 2004.
  • BS, Bacteriology, University of San Buenaventura , Cartagena, Colombia - 2002.
  •  
    Interdisciplinary & Emerging Signature Programs
    Allergy, Immunology & Infectious Disease, Cancer Biology.
     
    Research Summary

    Therapeutic vaccines for cancer are an attractive alternative to conventional therapies, since the later result in serious adverse effects and in most cases are not effective against advanced disease. Human papillomavirus (HPV) is responsible for several malignancies such as cervical carcinoma. Vaccines targeting oncogenic viral proteins like HPV16-E6 and HPV16-E7 are ideal candidates to elicit strong immune responses without generating autoimmunity because: (1) these products are not expressed in normal cells and (2) their expression is required to maintain the malignant phenotype. Our group has developed peptide vaccination strategy called TriVax, which is effective in generating vast numbers of antigen-specific T cells in mice capable of persisting for long time periods. We have used two HPV-induced mouse cancer models (TC-1 and C3.43) to evaluate the immunogenicity and therapeutic efficacy of TriVax prepared with the immunodominant CD8 T-cell epitope HPV16-E749-57, mixed with poly-IC adjuvant and costimulatory anti-CD40 antibodies. TriVax using HPV16-E749-57 induced large and persistent T-cell responses that were therapeutically effective against established HPV16-E7 expressing tumors. In most cases, TriVax was successful in attaining complete rejections of 6–11-day established tumors. In addition, TriVax induced long-term immunological memory, which prevented tumor recurrences. The anti-tumor effects of TriVax were independent of NK and CD4 T cells and, surprisingly, did not rely to a great extent on type-I or type-II interferon.

     
    Links

    Lab Link:  http://www.cancerbiology.usf.edu/celis.html


    Selected Publications
  • Barrios K, Celis E. TriVax: an improved therapeutic vaccination strategy against Human Papillomavirus-induced cancers Cancer Immunology Immunotherapy. (): , 2012.
  • Martínez B, Barrios K, Vergara C, Mercado D, Jiménez S, Caraballo L.A A NOS1 Gene Polymorphism Associated with Asthma and Specific Immunoglobulin E Response to Mite Allergens in a Colombian Population Int Arch Allergy Immunol. 2(144): 105-113, 2007.
  • Barrios K Técnicas básicas en genética molecular: Polimorfismos en la Longitud de los Fragmentos de Restricción (RFLP) Revista de Inmunoalergia . 2(13): 102-103, 2005.

  • Positions Held
  • Assistant Professor (Health Science, Bacteriology, University of San Buenaventura 2005 - 2008)


  • Profile last modified on 02/02/2013